Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Short Interest Down 17.8% in January

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) was the recipient of a large decrease in short interest in the month of January. As of January 30th, there was short interest totaling 5,133,106 shares, a decrease of 17.8% from the January 15th total of 6,246,481 shares. Based on an average daily volume of 1,070,048 shares, the short-interest ratio is currently 4.8 days. Approximately 9.0% of the shares of the company are sold short. Approximately 9.0% of the shares of the company are sold short. Based on an average daily volume of 1,070,048 shares, the short-interest ratio is currently 4.8 days.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR traded down $2.07 during trading on Monday, hitting $69.97. 1,252,099 shares of the company’s stock were exchanged, compared to its average volume of 977,623. The business’s 50-day simple moving average is $75.01 and its 200 day simple moving average is $43.40. The company has a market cap of $4.25 billion, a price-to-earnings ratio of -57.35 and a beta of -2.07. Structure Therapeutics has a 52-week low of $13.22 and a 52-week high of $94.90.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on GPCR. Citigroup reaffirmed an “outperform” rating on shares of Structure Therapeutics in a report on Friday, December 12th. Stifel Nicolaus boosted their price objective on shares of Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Piper Sandler restated an “overweight” rating on shares of Structure Therapeutics in a research note on Tuesday, October 28th. Jefferies Financial Group set a $125.00 target price on Structure Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $104.45.

Hedge Funds Weigh In On Structure Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of GPCR. CWM LLC lifted its stake in Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares in the last quarter. HighTower Advisors LLC increased its holdings in shares of Structure Therapeutics by 3.6% in the fourth quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock worth $648,000 after purchasing an additional 320 shares during the last quarter. State of Wyoming lifted its position in shares of Structure Therapeutics by 29.7% in the fourth quarter. State of Wyoming now owns 1,761 shares of the company’s stock worth $122,000 after buying an additional 403 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Structure Therapeutics by 9.4% during the third quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock valued at $135,000 after buying an additional 413 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Structure Therapeutics by 4.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock valued at $757,000 after buying an additional 444 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.